ALK and non-small cell lung carcinoma: Finally, we show that when H2228 cells expressing V3 are treated with a combination of the microtubule stabilizing drug, paclitaxel, and targeted ALK inhibitors they exhibit a synergistic response raising the prospect of a more effective approach to treating patients with NSCLC with EML4-ALK V3.